Meeting
2012 ASCO Annual Meeting
Impact of comorbidities on overall survival of high-risk and advanced melanoma.
Authors
Prashanth Peddi
University of Texas M. D. Anderson Cancer Center, Houston, TX
Prashanth Peddi , Jeong Hoon Oh , Kevin B. Kim , Jeffrey E. Gershenwald , Shana L. Palla , Christopher W Schacherer , Rakesh Jakkoju , Maria Suarez-Almazor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8536)
DOI
10.1200/jco.2012.30.15_suppl.8536
Abstract #
8536
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.
First Author: Olivier Jules van Not
Poster
2020 ASCO Virtual Scientific Program
Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).
First Author: Jason Alan Chesney
Poster
2019 ASCO Annual Meeting
Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).
First Author: Charlene Mantia
Poster
2014 ASCO Annual Meeting
Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small cell lung cancer.
First Author: Alex R. Menter